Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU
Rigel Pharmaceuticals signed an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
FDA approved vepdegestrant in May 2026 based on VERITAC-2 Phase 3 trial, showing 43% reduction in risk of disease progression or death vs. fulvestrant (median PFS:
5.0 vs. 2.1 months).
Rigel to launch VEPPANU in the U.S., pursue global rights, and contribute up to $40 million over four years for development.
Rigel Pharmaceuticals (RIGL) shares rose 10.69% to $29.00 following the announcement.